Baldwin Wealth Partners LLC MA Sells 103 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Baldwin Wealth Partners LLC MA lessened its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% during the fourth quarter, HoldingsChannel reports. The firm owned 5,622 shares of the medical research company’s stock after selling 103 shares during the quarter. Baldwin Wealth Partners LLC MA’s holdings in Thermo Fisher Scientific were worth $2,925,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the business. Daymark Wealth Partners LLC grew its holdings in shares of Thermo Fisher Scientific by 24.5% during the 2nd quarter. Daymark Wealth Partners LLC now owns 619 shares of the medical research company’s stock valued at $342,000 after purchasing an additional 122 shares during the last quarter. Kathmere Capital Management LLC bought a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $375,000. Driehaus Capital Management LLC boosted its holdings in shares of Thermo Fisher Scientific by 75.0% during the 2nd quarter. Driehaus Capital Management LLC now owns 1,524 shares of the medical research company’s stock valued at $843,000 after acquiring an additional 653 shares in the last quarter. Ascent Group LLC increased its holdings in Thermo Fisher Scientific by 5.4% in the 2nd quarter. Ascent Group LLC now owns 11,029 shares of the medical research company’s stock worth $6,099,000 after purchasing an additional 561 shares in the last quarter. Finally, Aviso Wealth Management boosted its stake in shares of Thermo Fisher Scientific by 9.9% during the second quarter. Aviso Wealth Management now owns 1,596 shares of the medical research company’s stock valued at $883,000 after purchasing an additional 144 shares in the last quarter. Institutional investors and hedge funds own 89.23% of the company’s stock.

Insider Activity at Thermo Fisher Scientific

In other news, CEO Marc N. Casper sold 10,000 shares of the stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total value of $5,581,200.00. Following the completion of the sale, the chief executive officer now owns 33,608 shares in the company, valued at $18,757,296.96. This represents a 22.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last three months, insiders sold 34,850 shares of company stock valued at $19,123,197. 0.34% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research firms recently commented on TMO. Wells Fargo & Company cut their target price on shares of Thermo Fisher Scientific from $670.00 to $660.00 and set an “overweight” rating on the stock in a research report on Thursday, October 24th. Bernstein Bank increased their price objective on Thermo Fisher Scientific from $565.00 to $625.00 and gave the company a “market perform” rating in a report on Tuesday, October 22nd. Stifel Nicolaus reduced their price target on Thermo Fisher Scientific from $680.00 to $665.00 and set a “buy” rating on the stock in a research report on Thursday, October 24th. StockNews.com raised Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a research note on Tuesday, January 14th. Finally, Royal Bank of Canada lowered their price target on shares of Thermo Fisher Scientific from $767.00 to $718.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Four analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Trading Down 0.1 %

TMO opened at $574.21 on Monday. The firm has a market capitalization of $219.63 billion, a PE ratio of 36.04, a P/E/G ratio of 3.82 and a beta of 0.76. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.63 and a quick ratio of 1.26. Thermo Fisher Scientific Inc. has a fifty-two week low of $493.30 and a fifty-two week high of $627.88. The company’s 50-day moving average is $533.60 and its 200 day moving average is $569.81.

Thermo Fisher Scientific declared that its board has approved a stock buyback program on Friday, November 15th that permits the company to buyback $4.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s leadership believes its shares are undervalued.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, January 15th. Investors of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. Thermo Fisher Scientific’s payout ratio is 9.78%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.